<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-5044</journal-id>
<journal-title><![CDATA[Revista mexicana de neurociencia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. neurocienc.]]></abbrev-journal-title>
<issn>1665-5044</issn>
<publisher>
<publisher-name><![CDATA[Academia Mexicana de Neurología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-50442023000300071</article-id>
<article-id pub-id-type="doi">10.24875/rmn.22000081</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Guillain-Barre syndrome with hyponatremia, more than a simple finding]]></article-title>
<article-title xml:lang="es"><![CDATA[Síndrome de Guillain-Barre con hiponatremia, más que un simple hallazgo]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Piña]]></surname>
<given-names><![CDATA[Daniel A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Medina-Gómez]]></surname>
<given-names><![CDATA[Victor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Hernández]]></surname>
<given-names><![CDATA[José F.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas-Cañas]]></surname>
<given-names><![CDATA[Edwin S.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Violante-Villanueva]]></surname>
<given-names><![CDATA[Arturo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Hernández]]></surname>
<given-names><![CDATA[Juan C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,National Institute of Neurology and Neurosurgery Dr. Manuel Velasco Suarez Department of Neurology ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,National Institute of Neurology and Neurosurgery Dr. Manuel Velasco Suarez Clinic of Neuromuscular Diseases ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,National Institute of Neurology and Neurosurgery Dr. Manuel Velasco Suarez Department of Neurological Emergencies ]]></institution>
<addr-line><![CDATA[Mexico City ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>24</volume>
<numero>3</numero>
<fpage>71</fpage>
<lpage>77</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-50442023000300071&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-50442023000300071&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-50442023000300071&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Hyponatremia occurs in 21-48% of patients with Guillain-Barre syndrome (GBS). However, little is known about the clinical implications in GBS.  Materials and methods: In this observational, cross-sectional study, of patients diagnosed with GBS was conducted. Information used included: demographic clinical variables, cerebrospinal fluid (CSF) results, and nerve conduction studies. Patients with sodium levels &lt; 135 meq/L in laboratory studies on admission and before treatment were considered to have hyponatremia. We defined good functional prognosis as the presence of independent gait (Hughes &#8804; 2 points) at 3 months of follow-up.  Results: Two hundred and twelve patients were initially screen and 31 (14.6%) presented hyponatremia; male gender was predominant with 72%, mean age was 45.9 ± 16 years, mean Modified Medical Research Council (MRC) score was 30.1 ± 17 points, invasive mechanical ventilation requirement was 32%, and the presence of dysautonomia 32%. One hundred and eighty-two nerve conduction studies, and 165 CSF cytochemical samples were collected. In the comparative analyses between the patients with hyponatremia versus without hyponatremia, we observed significant differences in mean age (50.4 ± 14.9 vs. 43.8 ± 16.3, p = 0.03), days of hospitalization (median) (16 [IQR = 7-51] vs. 7 [IQR = 5-12] p = 0.03), dysautonomia (54.8% vs. 28.2%, p = 0.006), protein levels (mgs/dL) in CSF (median) (105 [IQR = 59-165] vs. 39 [IQR = 28-57], p &#8804; 0.001), and acute inflammatory demyelinating polyneuropathy (AIDP) variant (70.4% vs. 42%, p = 0.011). There was no significant finding in recovery of independent gait at 3 months (34.6% vs. 42.6%, p = 0.51).  Conclusion: About 14% of patients with GBS presented with hyponatremia in our series and is associated with presence of dysautonomia, AIDP variant, elevated CSF protein levels and a greater number of days of hospital stay but did not impact functional prognosis.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La hiponatremia se presenta en el 21,5-48% de los pacientes con síndrome de Guillaín-Barré (SGB), sin embargo, existe poca información sobre sus implicaciones clínicas en el SGB.  Material y métodos: Se realizó un estudio observacional, transversal, de pacientes con diagnóstico de SGB. Recabamos información de variables clínicas, resultado del LCR y conducción nerviosa. Los pacientes con niveles de sodio &lt; 135 meq/L en estudios de laboratorio al ingreso y antes del inicio de tratamiento fueron considerados con hiponatremia. Definimos buen pronóstico funcional a la presencia de marcha independiente (Hughes &#8804; 2 puntos) a los 3 meses de seguimiento.  Resultados: De 212 pacientes, 31 (14.6%) presentaron hiponatremia, sexo masculino 72%, edad promedio 45.9 ± 16 años, MRC score 30.1 ± 17 puntos, requerimiento de VMI 32%, presencia de disautonomía 32%. Recabamos ciento ochenta y dos estudios de conducción nerviosa y 165 resultados citoquímicos de punción lumbar. En el análisis comparativo entre los pacientes con hiponatremia vs sin hiponatremia, observamos diferencias significativas: edad (50.4 ± 14,9 vs. 43.8 ± 16.3, p = 0.03), días de hospitalización (mediana) (16 [IQR = 7-51] vs. 7 [IQR = 5-12] p = 0.03), disautonomía (54.8% vs. 28.2%, p = 0.006), niveles de proteínas (mgs/dL) en LCR (mediana) (105 [IQR = 59-165] vs. 39 [IQR = 28-57], p &#8804; 0.001) y variante AIDP (70.4% vs. 42%, p = 0.011); En la recuperación de la marcha a los 3 meses, no hubo diferencia significativa (34,6% vs. 42,6%, p = 0.51).  Conclusión: 14% de los pacientes con SGB presentan hiponatremia, con formas clínicas más severas, presencia de disautonomía, variante de AIDP más frecuente, niveles elevados de proteínas en LCR y mayor número de días de estancia hospitalaria, pero no afecta el pronóstico funcional.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Guillain-Barre syndrome]]></kwd>
<kwd lng="en"><![CDATA[Hyponatremia]]></kwd>
<kwd lng="en"><![CDATA[Clinical presentation]]></kwd>
<kwd lng="en"><![CDATA[Functional prognosis]]></kwd>
<kwd lng="es"><![CDATA[Síndrome de Guillain-Barre]]></kwd>
<kwd lng="es"><![CDATA[Hiponatremia]]></kwd>
<kwd lng="es"><![CDATA[Presentación clínica]]></kwd>
<kwd lng="es"><![CDATA[Pronóstico funcional]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shahrizaila]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lehmann]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwabara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<page-range>1214-28</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sejvar]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Baughman]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Wise]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Population incidence of Guillain-Barrésyndrome:a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Neuroepidemiology]]></source>
<year>2011</year>
<volume>36</volume>
<page-range>123-33</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galnares-Olalde]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[López-Hernández]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[García-Grimshaw]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés-Ferrer]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Briseño-Godínez]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[de-Sarachaga]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barrésyndrome in Mexico:an updated review amid the coronavirus disease 2019 ERA]]></article-title>
<source><![CDATA[Rev Invest Clin]]></source>
<year>2022</year>
<volume>74</volume>
<page-range>121-30</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Hernández]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Colunga-Lozano]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Trejo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Figueroa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado-Garcia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bazán-Rodríguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Electrophysiological subtypes and associated prognosis factors of Mexican adults diagnosed with Guillain-Barrésyndrome, a single center experience]]></article-title>
<source><![CDATA[J Clin Neurosci]]></source>
<year>2020</year>
<volume>80</volume>
<page-range>292-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Podestà]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Faravelli]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cucchiari]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Reggiani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Oldani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fedeli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurological counterparts of hyponatremia:pathological mechanisms and clinical manifestations]]></article-title>
<source><![CDATA[Curr Neurol Neurosci Rep]]></source>
<year>2015</year>
<volume>15</volume>
<page-range>18</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Gang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inappropriate antidiuretic hormone secretion and cerebral salt-wasting syndromes in neurological patients]]></article-title>
<source><![CDATA[Front Neurosci]]></source>
<year>2019</year>
<volume>13</volume>
<page-range>1170</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peric]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berisavac]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Tamas]]></surname>
<given-names><![CDATA[OS]]></given-names>
</name>
<name>
<surname><![CDATA[Rajic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Babic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cvijanovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barrésyndrome in the elderly]]></article-title>
<source><![CDATA[J Peripher Nerv Syst]]></source>
<year>2016</year>
<volume>21</volume>
<page-range>105-10</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hosseininezhad]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khatami]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saadat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Asghari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Choshal]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Marvasti]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ten years evaluation of epidemiology-and mortality-related factors in adults and children with Guillain-Barrésyndrome in the North of Iran]]></article-title>
<source><![CDATA[Neurol Sci]]></source>
<year>2022</year>
<volume>43</volume>
<page-range>1929-38</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vega]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[León]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Baturone]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barrésyndrome and hyponatraemia]]></article-title>
<source><![CDATA[Neurologia (Engl Ed)]]></source>
<year>2020</year>
<volume>35</volume>
<page-range>282-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jose]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Syndrome of inappropriate secretion of antidiuretic hormone preceding Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[J Clin Diagn Res]]></source>
<year>2017</year>
<volume>11</volume>
<page-range>OD16-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lenhard]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Grimm]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ringleb]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Renal salt wasting as part of dysautonomia in Guillain-Barre syndrome]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2011</year>
<volume>82</volume>
<page-range>1051-3</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anandan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Khuder]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Koffman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of autonomic dysfunction in hospitalized patients with Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2017</year>
<volume>56</volume>
<page-range>331-3</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gagliardi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Faravelli]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Podestà]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Brusa]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mauri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Saccomanno]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium levels predict disability at discharge in Guillain-BarréSyndrome:a retrospective cohort study]]></article-title>
<source><![CDATA[Front Neurol]]></source>
<year>2021</year>
<volume>12</volume>
<page-range>729252</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intensive care and treatment of severe Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[Front Pharmacol]]></source>
<year>2021</year>
<volume>12</volume>
<page-range>608130</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saifudheen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jose]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gafoor]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Musthafa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barre syndrome and SIADH]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>2011</year>
<volume>76</volume>
<page-range>701-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zemke]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Boles]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Gillespie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Viljoen]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barrésyndrome hyponatremia:is it SIADH or pseudohyponatremia?]]></article-title>
<source><![CDATA[Oxf Med Case Rep]]></source>
<year>2018</year>
<volume>7</volume>
<page-range>248-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramanathan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hyponatraemic encephalopathy as the initial presentation of Guillain-Barre syndrome]]></article-title>
<source><![CDATA[Med J Malaysia]]></source>
<year>2008</year>
<volume>63</volume>
<page-range>426-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramanathan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McMeniman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cabela]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Holmes-Walker]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fung]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SIADH and dysautonomia as the initial presentation of Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2012</year>
<volume>83</volume>
<page-range>344-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Hernández]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[May-Mas]]></surname>
<given-names><![CDATA[RN]]></given-names>
</name>
<name>
<surname><![CDATA[Galnares-Olalde]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Bazán-Rodríguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[de Saráchaga]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Jiménez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Very-early Guillain-Barrésyndrome:clinical characteristics, electrophysiological findings, and short-term functional outcome]]></article-title>
<source><![CDATA[Rev Mex Neurosci]]></source>
<year>2021</year>
<volume>22</volume>
<page-range>173-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shekhar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Harisingani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nikita]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abdominal pain followed by altered mental status:a rare presentation of Guillain Barrésyndrome]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2022</year>
<volume>14</volume>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sipilä]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Kauko]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Soilu-Hänninen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Admission sodium level and prognosis in adult Guillain-Barrésyndrome]]></article-title>
<source><![CDATA[Int J Neurosci]]></source>
<year>2017</year>
<volume>127</volume>
<page-range>344-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santoro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra]]></surname>
<given-names><![CDATA[T D]]></given-names>
</name>
<name>
<surname><![CDATA[Errico]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fraddosio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lapenna]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Introna]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain-Barrésyndrome associated with inappropriate secretion of antidiuretic hormone following SARS-CoV-2 infection:a case-report]]></article-title>
<source><![CDATA[Clin Case Rep]]></source>
<year>2021</year>
<volume>9</volume>
<page-range>c04667</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
